Search

Search Results

• 

  PO51 | MECHANISTIC POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF FACTOR XI-TARGETING MONOCLONAL ANTIBODIES SUPPORTS DURABLE ANTICOAGULANT COVERAGE AND TRANSLATIONAL DOSE AND REGIMEN SELECTION O. Milberg¹, H. Abdallah¹, R.K. Lokken², R. Dingman¹, K.A. Meagher¹, M.E. Burczynski¹, E. Marin¹, A.P. Kithcart¹, D. E. Gutstein¹ | ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; ²Allucent, Cary, NC, USA

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.543

  109

  PDF: 24
• 

  PO50 | SUB-ANALYSIS OF INTERIM RESULTS FROM A PHASE 2 STUDY INVESTIGATING REGN9933^A2 AND REGN7508^CAT FOR THE PREVENTION OF CONTACT-MEDIATED VENOUS THROMBOEMBOLISM IN PATIENTS WITH ACTIVE CANCER UNDERGOING PERIPHERALLY INSERTED CENTRAL CATHETER PLACEMENT (ROXI-CATH) J. Zwicker^1,2, A.P. Kithcart³, J. Kaplan³, Y-C. Cheng³, J.G. Raya³, J. Xiao³, S. Li³, K. Musgrave⁴, D.E. Gutstein³, G. Piazza⁵ | ¹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Weill Cornell Medical Center, New York, NY, USA; ³Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; ⁴Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; ⁵Brigham and Women’s Hospital, Boston, MA, USA

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.542

  118

  PDF: 29
• 

  OC09 | BLEEDING RISK ASSOCIATED WITH FACTOR XI MONOCLONAL ANTIBODIES IN COMBINATION WITH ASPIRIN IN HEALTHY VOLUNTEERS AND ORTHOPEDIC SURGERY PATIENTS: ANALYSIS FROM RECENT PHASE 1 AND PHASE 2 STUDIES A.P. Kithcart¹, M.E. Burczynski¹, P. Banerjee¹, M. Onisko¹, Y. Wang¹, K. Mohammadi¹, D. Li¹, S. Li¹, J. Ackroyd², B.A. Olenchock¹, D.E. Gutstein¹, J. I. Weitz³ | ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; ²Clinical Research, Fortrea Clinical Research Unit Ltd, Leeds, UK; ³McMaster University, Hamilton, ON, Canada

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.492

  102

  PDF: 36
• 

  PO53 | PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF REGN7508^CAT FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I) J. Zwicker¹, M. P. O’Brien², M. Carrier³, J. Connors⁴, A. Falanga⁵, A. Manzano⁶, R. Mcbane⁷, Y.Y. Janjigian¹, G. O’Kane⁸, M. Onisko², J. Kaplan², A.P. Kithcart², D.E. Gutstein², A. Khorana⁹, M. F. Walsh² | ¹Memorial Sloan Kettering Cancer Center, New York, USA; ²Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; ³University of Ottawa, Ottawa, ON, Canada; ⁴Harvard Medical School, Boston, MA, USA; ⁵Hospital Papa Giovanni XXIII, Bergamo, Italy; ⁶Hospital Universitario 12 de Octubre, Madrid, Spain; ⁷Mayo Clinic, Rochester, MN, USA; ⁸St. Vincent's University Hospital and School of Medicine, University College Dublin, Dublin, Ireland; ⁹James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.545

  112

  PDF: 29
• 

  PO52 | MECHANISTIC POPULATION PHARMACOKINETIC/PHARMACODYNAMIC AND TIME-TO-EVENT MODELING SUPPORT SUSTAINED FACTOR XI INHIBITION AND SUPERIOR POST-OPERATIVE VENOUS THROMBOEMBOLISM PREVENTION WITH REGN7508^CAT O. Milberg¹, H. Abdallah¹, R.K. Lokken², R. Dingman¹, K.A. Meagher¹, P. Banerjee¹, M.E. Burczynski¹, E. Marin¹, A.P. Kithcart¹, D.E. Gutstein¹ | ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; ²Allucent, Cary, NC, USA

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.544

  101

  PDF: 24